Citigroup Cuts Abbott Laboratories (ABT) Price Target to $122

Citigroup reaffirmed its Buy rating on Abbott Laboratories ABT on October 22, 2026, while adjusting its price target down from $125.00 to $122.00.

ABT Abbott Laboratories

$100.51 ▼ -17.06% year to date

1M 3M YTD

Daily close · Oct 21, 2026

{Firm}'s Call on {Company}

In its research note on October 22, 2026, Citigroup maintained its positive stance on the medical device maker while trimming its twelve-month price objective by $3.00. Several other major research firms updated their views on the same day, with RBC Capital keeping an Outperform rating and moving its target from $130.00 to $125.00. Wells Fargo maintained an Overweight rating while lifting its target to $119.00 from $112.00. JP Morgan kept an Overweight rating and adjusted its target from $120.00 to $118.00. TD Cowen maintained a Buy rating while lowering its target from $135.00 to $118.00. Wall Street currently maintains a strong buy consensus on the stock with a mean target of about $120.41 across 26 analyst opinions.

Other Institutional Activity in {Company}

Capital International Investors reduced its holdings by 2,842,222 shares, ending with 34,654,113 shares worth about $3,552,393,197.

Abbott Laboratories Stock Up 0.1%

Abbott Laboratories recently traded around $102.53 on October 22, 2026, closing that day at $102.51. The share price sits below its 50-day moving average of $105.49 and close to its 200-day moving average of $102.46. The stock has traded between a 52-week low of $81.97 and a 52-week high of $132.03.

Recent Earnings

Abbott Laboratories posted trailing twelve-month revenue of $46,585,000,000 with earnings of $2.69 per share. The company reported a net profit margin of 11.6% and a return on equity of 10.6%.

Dividend

Abbott Laboratories pays an annual dividend of $2.52 per share, which translates to a dividend yield of 2.46%. The company distributes 78.7% of its earnings as dividends.

Insider Buying and Selling at Abbott Laboratories

Abbott Laboratories saw multiple insider transactions over the months preceding the analyst update. Director John G. Stratton acquired 2,000 shares on May 7, 2026, at an average price of $86.82 for a total value of $173,640. Officer Louis H Morrone sold 5,850 shares on August 11, 2026, at $109.83 per share, totaling $642,506. Chief Executive Officer Robert B. Ford disposed of 398,832 shares on August 25, 2026, valued at $46,204,798. Officer John A. Mccoy Jr sold 27 shares on September 2, 2026, at $109.54 per share, amounting to $2,958.

About {Company}

Headquartered in Abbott Park, Illinois, Abbott Laboratories discovers, develops, manufactures, and sells health care products globally. The company operates across four primary segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.

Bottom Line

Investors will want to watch for upcoming earnings reports and further institutional filings to see how the medical device sector performs through the rest of the year. Analyst target adjustments reflect ongoing adjustments to valuation expectations across the healthcare industry.